ArticleHuman vaccines & immunotherapeutics2025
Serotype 3 invasive pneumococcal disease in Tuscany across the eras of conjugate vaccines (2005-2024) and anthropic-driven respiratory virus fluctuations.
Article in Human vaccines & immunotherapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Article
- Erratum: Pneumococcal Vaccination of Adults in Italy: What Strategies?Journal of preventive medicine and hygiene · 2025Article
- Invasive Pneumococcal Diseases Before and After the COVID-19 Pandemic in Italy (2018-2023).Microorganisms · 2025Article
- Pneumococcal Vaccination of Adults in Italy: What Strategies?Journal of preventive medicine and hygiene · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Serotype 3 Streptococcus pneumoniae (ser3) has emerged as a leading cause of invasive pneumococcal disease (IPD) despite targeted vaccination efforts. Preliminary evidence reported a differential impact of anti-ser3-pneumococcal-conjugate-vaccines (PCVser3) on different clinical presentations of ser3-IPD. Recently, a temporal association between respiratory syncytial virus (RSV) and IPD was observed in children, supporting a role of RSV in driving IPD dynamics. Ser3 IPD cases occurred in Tuscany from November 2005 to March 2024 were included. Comparisons of different clinical presentations (bacteremic pneumonias and osteomyelitis versus sepsis and meningitis) were made between younger and older patients and between vaccinated and unvaccinated ones. The temporal correlation between ser3 IPD, RSV and influenza was qualitatively described from 2015/2016 to 2023/2024. Among 160 ser3 IPD recorded cases, fully-immunized patients showed a significantly lower proportion of sepsis and meningitis compared to non-immunized patients (all ages: 7.5% versus 58.5%,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.